Invertase for Pharmaceutical and Medical Nutrition Fructose Syrup Production
Produce high-purity fructose-containing syrups for pharmaceutical excipient, parenteral nutrition, and medical nutrition applications using food-grade invertase enzyme for clean, controlled sucrose hydrolysis.
Fructose and fructose-containing syrups occupy a specialized role in pharmaceutical and medical nutrition applications where their distinct metabolic properties — partial insulin-independent metabolism, lower glycemic index compared to glucose, and high sweetness per calorie — make them preferable to sucrose or glucose in specific clinical contexts. Pharmaceutical-grade fructose is used as an excipient in oral liquid formulations for diabetic patients, as a sweetener and caloric source in enteral nutrition products, and as a carbohydrate component in parenteral nutrition solutions in some markets. Enzymatic production of fructose-containing syrups from sucrose using invertase enzyme (EC 3.2.1.26) from Saccharomyces cerevisiae provides a clean, controlled route to high-quality glucose-fructose mixture without acid salt residues, heavy metal contamination from catalysts, or process byproducts that complicate pharmaceutical-grade purification. The invertase reaction at pH 4.0–5.5 and 50–60°C produces a 1:1 glucose-fructose syrup with high conversion efficiency (>98% sucrose hydrolysis achievable). For pharmaceutical applications requiring purified fructose rather than invert sugar mixture, the enzyme inversion step provides the glucose-fructose feedstock for subsequent chromatographic separation (simulated moving bed, SMB) to produce high-purity fructose at >99% purity. For medical nutrition and enteral feeding — where complete sucrose hydrolysis in sucrose-intolerant patients is required — invertase enzyme treatment of sucrose-based feed formulations provides pre-digested monosaccharide carbohydrates that can be absorbed without sucrase-isomaltase enzyme at the intestinal brush border. Technical buyers in pharmaceutical ingredients and contract manufacturing specify invertase enzyme with pharmaceutical-grade documentation standards, including identity, purity, microbial quality, and absence of heavy metals, in addition to the standard food-grade certifications.
Invert sugar production as pharmaceutical oral liquid excipient
Pharmaceutical oral liquid formulations — syrups, suspensions, and elixirs — frequently use sucrose or invert sugar as a sweetening and viscosity-building excipient. For formulations targeting diabetic patients or sucrase-deficient individuals, invertase-produced invert sugar (glucose-fructose 1:1) is preferable to sucrose because it requires no intestinal sucrase activity for absorption. Invertase enzyme at 300–500 U/kg sucrose, pH 4.5–5.0, 55–60°C, converts sucrose to invert within 2–3 hours, producing the monosaccharide-based excipient syrup for pharmaceutical compounding.
Enteral nutrition formula carbohydrate preparation
Enteral nutrition formulas for patients with sucrase-isomaltase deficiency, inflammatory bowel disease affecting carbohydrate absorption, or specific metabolic conditions require carbohydrates in monosaccharide form. Invertase enzyme treatment of sucrose-containing formula concentrates at 200–400 U/kg sucrose, 50–55°C, pH 4.5–5.5, converts sucrose to glucose and fructose before pasteurization and packaging, providing an immediately absorbable carbohydrate source in the finished enteral product.
High-purity fructose feedstock for pharmaceutical chromatographic separation
Production of pharmaceutical-grade high-purity fructose (>99%) begins with enzymatic sucrose inversion using invertase to produce the glucose-fructose feedstock before simulated moving bed (SMB) chromatographic separation. Invertase enzyme at 300–500 U/kg sucrose, pH 4.5–5.0, 55–60°C, provides >98% sucrose conversion within 2–4 hours, generating a clean glucose-fructose feed solution free of acid salt contaminants for the SMB separation unit. Chromatographic fructose production requires minimal impurities in the feed, making enzymatic inversion — versus acid hydrolysis — the process-of-choice for pharmaceutical-grade fructose manufacturing.
Low-glycemic sweetener production for medical nutrition products
Medical nutrition products for metabolic disease management — diabetes, obesity, and glycogen storage disorders — use fructose and invert sugar as lower-glycemic sweetening systems compared to glucose or sucrose. Invertase-produced invert sugar at 75–78 Brix is formulated into medical food bars, powders, and liquid supplements where glycemic response management is a clinical objective. The enzymatic route ensures complete sucrose conversion and eliminates residual sucrose that would raise the glycemic index of the finished product above the target for the metabolic indication.
| Parameter | Value |
| Activity range | 100,000 – 300,000 SU/g |
| Optimal pH | 4.0 – 5.5 |
| Optimal temperature | 50°C – 60°C |
| Form | Light yellow to amber powder or liquid |
| Shelf life | 12 months (sealed, cool, dry place) |
| Packaging | 25 kg drums / 25 kg jerricans |
Frequently Asked Questions
What documentation is available for invertase enzyme in pharmaceutical applications?
For pharmaceutical and medical nutrition applications, invertase enzyme must be supplied with documentation beyond standard food-grade certification. We provide COA with activity assay, identity (FTIR or electrophoresis), microbial quality (total plate count, Enterobacteriaceae, yeast and mold), heavy metals screen, and allergen status. ISO 9001, HALAL, and KOSHER certificates are included. For applications requiring pharmacopeial-grade specifications — such as European Pharmacopeia (Ph.Eur.) or US Pharmacopeia (USP) monograph compliance — buyers should discuss their specific documentation needs with our quality team, as additional testing and DMF-style documentation may be available for qualified pharmaceutical buyers.
Why is fructose used in pharmaceutical formulations instead of sucrose or glucose?
Fructose has several pharmacological advantages over sucrose and glucose in specific clinical contexts. First, fructose is partially metabolized without insulin stimulation in the liver, making it historically used in formulations for diabetic patients — though this use requires careful clinical consideration due to fructose's association with metabolic effects at high doses. Second, fructose is approximately 1.2–1.7 times sweeter than sucrose at equivalent mass, so less sweetener is needed per formulation. Third, patients with sucrase-isomaltase deficiency cannot digest sucrose but can absorb fructose directly via GLUT5. In enteral nutrition for these patients, invertase-pre-hydrolyzed sucrose provides the carbohydrate in absorbable monosaccharide form.
Can invertase enzyme be used to produce fructose for parenteral (intravenous) nutrition?
Invertase enzyme inversion of sucrose produces a glucose-fructose invert sugar that historically was used as a parenteral nutrition carbohydrate source. Parenteral use of fructose has become less common in contemporary clinical practice due to concerns about fructose-induced lactic acidosis in some patient populations, and most current parenteral nutrition protocols use glucose (dextrose) as the primary carbohydrate. Buyers considering invertase-produced fructose for parenteral applications should consult current clinical pharmacopoeia standards and their formulation medical advisors. We do not provide clinical advice; we provide the enzyme with food-grade documentation, and buyers are responsible for assessing clinical suitability.
What purity of fructose can be achieved by invertase sucrose hydrolysis alone without chromatography?
Invertase enzyme hydrolysis of sucrose produces a product that is approximately 50% glucose and 50% fructose on a dry matter basis (invert sugar), plus water and trace amounts of enzyme protein. The reaction does not enrich fructose beyond the 1:1 molar ratio from sucrose hydrolysis. To achieve high-purity fructose (>90%, >95%, or >99%), the invert sugar from enzymatic hydrolysis must be further processed by chromatographic separation using SMB (simulated moving bed) or similar ion exchange chromatography systems. The invertase enzyme step produces the clean, monosaccharide feedstock for this separation. Invertase-produced invert sugar at >98% sucrose conversion is the preferred feedstock for SMB fructose production because it contains minimal residual sucrose that would otherwise complicate the chromatographic separation.
Source Invertase for Pharmaceutical-Grade Fructose Production
Share your application, target pH/temperature, and annual demand. We'll recommend the right activity grade and send a free sample with COA/TDS within 24 hours.
Get Quote